Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report issued on Thursday morning,Benzinga reports. Chardan Capital currently has a $14.00 price target on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, March 18th.

Coya Therapeutics Trading Up 3.2 %

COYA stock opened at $6.68 on Thursday. The firm has a 50 day moving average of $6.33 and a 200-day moving average of $6.49. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.24. The company has a market cap of $111.72 million, a price-to-earnings ratio of -10.28 and a beta of 0.31.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.10 million. Sell-side analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after buying an additional 4,777 shares during the period. XTX Topco Ltd purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at $59,000. Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at $74,000. Northern Trust Corp grew its stake in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after buying an additional 3,099 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at $401,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.